Literature DB >> 29661770

Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis.

Chia-Lin Wu1, Chia-Chu Chang1, Chew-Teng Kor1, Tao-Hsiang Yang1, Ping-Fang Chiu1, Der-Cherng Tarng2, Chih-Cheng Hsu2.   

Abstract

BACKGROUND AND OBJECTIVES: Hydroxychloroquine is widely used in patients with rheumatoid arthritis. However, large-scale studies examining the long-term effects of hydroxychloroquine on the development of kidney disease in patients with rheumatoid arthritis are lacking. We aimed to assess the long-term association of hydroxychloroquine use with the risk of developing CKD in this population. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted an observational cohort study for patients with newly diagnosed rheumatoid arthritis who were enrolled prospectively in Taiwan's National Health Insurance Research Database between January 1, 2000 and December 31, 2013. We used multivariable Cox proportional hazard regression to analyze the association of hydroxychloroquine use with incident CKD.
RESULTS: A total of 2619 patients, including 1212 hydroxychloroquine users and 1407 hydroxychloroquine nonusers, were analyzed. Incident CKD was reported in 48 of 1212 hydroxychloroquine users and 121 of 1407 hydroxychloroquine nonusers. The incidence rate of CKD was lower in hydroxychloroquine users than in hydroxychloroquine nonusers (10.3 versus 13.8 per 1000 person-years). After multivariable adjustment, hydroxychloroquine users still had a lower risk of incident CKD (adjusted hazard ratio, 0.64; 95% confidence interval, 0.45 to 0.90; P=0.01) than hydroxychloroquine nonusers. The lower risk of subsequent CKD development was dose dependent and consistent across subgroup analyses.
CONCLUSIONS: Hydroxychloroquine use in patients with newly diagnosed rheumatoid arthritis is associated with a significantly lower risk of incident CKD compared with in nonusers.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Arthritis, Rheumatoid; Cohort Studies; Confidence Intervals; Humans; Hydroxychloroquine; Incidence; National Health Programs; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk; Taiwan; chronic kidney disease; hydroxychloroquine; rheumatoid arthritis

Mesh:

Substances:

Year:  2018        PMID: 29661770      PMCID: PMC5969483          DOI: 10.2215/CJN.11781017

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  28 in total

1.  STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. VI. THE PHYSIOLOGICAL DISPOSITION, ANTIMALARIAL ACTIVITY, AND TOXICITY OF SEVERAL DERIVATIVES OF 4-AMINOQUINOLINE.

Authors:  R W Berliner; D P Earle; J V Taggart; C G Zubrod; W J Welch; N J Conan; E Bauman; S T Scudder; J A Shannon
Journal:  J Clin Invest       Date:  1948-05       Impact factor: 14.808

2.  Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy.

Authors:  Ruitong Gao; Wei Wu; Yubing Wen; Xuemei Li
Journal:  Int Urol Nephrol       Date:  2017-03-27       Impact factor: 2.370

Review 3.  Rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Iain B McInnes
Journal:  Lancet       Date:  2016-05-03       Impact factor: 79.321

4.  Failure of ICD-9-CM codes to identify patients with comorbid chronic kidney disease in diabetes.

Authors:  Elizabeth F O Kern; Miriam Maney; Donald R Miller; Chin-Lin Tseng; Anjali Tiwari; Mangala Rajan; David Aron; Leonard Pogach
Journal:  Health Serv Res       Date:  2006-04       Impact factor: 3.402

5.  Increased risk of stroke in patients with chronic kidney disease after recurrent hypoglycemia.

Authors:  Tung-Min Yu; Cheng-Li Lin; Shih-Ni Chang; Fung-Chang Sung; Chia-Hung Kao
Journal:  Neurology       Date:  2014-07-16       Impact factor: 9.910

Review 6.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis.

Authors:  Laurence Beck; Andrew S Bomback; Michael J Choi; Larry B Holzman; Carol Langford; Laura H Mariani; Michael J Somers; Howard Trachtman; Meryl Waldman
Journal:  Am J Kidney Dis       Date:  2013-07-18       Impact factor: 8.860

7.  Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study.

Authors:  S Karie; F Gandjbakhch; N Janus; V Launay-Vacher; S Rozenberg; C U Mai Ba; P Bourgeois; G Deray
Journal:  Rheumatology (Oxford)       Date:  2008-01-31       Impact factor: 7.580

Review 8.  [Kidney involvement in rheumatoid arthritis].

Authors:  A Icardi; P Araghi; M Ciabattoni; U Romano; P Lazzarini; G Bianchi
Journal:  Reumatismo       Date:  2003

9.  Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis.

Authors:  Masako Kochi; Kentaro Kohagura; Yoshiki Shiohira; Kunitoshi Iseki; Yusuke Ohya
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

10.  Long-term renal outcomes in patients with traumatic brain injury: A nationwide population-based cohort study.

Authors:  Chia-Lin Wu; Chew-Teng Kor; Ping-Fang Chiu; Chun-Chieh Tsai; Ie-Bin Lian; Tao-Hsiang Yang; Der-Cherng Tarng; Chia-Chu Chang
Journal:  PLoS One       Date:  2017-02-14       Impact factor: 3.240

View more
  12 in total

1.  Antimalarial Drugs for the Prevention of Chronic Kidney Disease in Patients with Rheumatoid Arthritis: The Importance of Controlling Chronic Inflammation?

Authors:  Jennifer C Rodrigues; Joanne M Bargman
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-16       Impact factor: 8.237

2.  Hydroxychloroquine-induced podocytopathy mimicking Fabry disease.

Authors:  Justine Serre; David Buob; Jean-Jacques Boffa
Journal:  BMJ Case Rep       Date:  2019-05-13

3.  Effects of hydroxychloroquine on proteinuria in membranous nephropathy.

Authors:  Yan-Jiao Cheng; Xu-Yang Cheng; Yi-Miao Zhang; Fang Wang; Xin Wang; Li-Qiang Meng; Gang Liu; Zhao Cui; Ming-Hui Zhao
Journal:  J Nephrol       Date:  2021-11-30       Impact factor: 3.902

4.  Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction.

Authors:  Jung Sun Lee; Ji Seon Oh; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo; Seokchan Hong
Journal:  Rheumatol Int       Date:  2020-03-13       Impact factor: 2.631

Review 5.  Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.

Authors:  Yan Chen; TaiPeng Shen; LiJun Zhong; ZhiXi Liu; XinWei Dong; TingWenLi Huang; QiuJu Wang; HongTao Xiao
Journal:  Front Pharmacol       Date:  2020-07-31       Impact factor: 5.810

Review 6.  Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues.

Authors:  Ashutosh M Shukla; Aparna Wagle Shukla
Journal:  Drugs Context       Date:  2019-11-25

7.  Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study.

Authors:  Ya-Zi Yang; Pei Chen; Li-Jun Liu; Qing-Qing Cai; Su-Fang Shi; Yu-Qing Chen; Ji-Cheng Lv; Hong Zhang
Journal:  BMC Nephrol       Date:  2019-08-05       Impact factor: 2.388

Review 8.  Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?

Authors:  Gerwyn Morris; Eugene Athan; Ken Walder; Chiara C Bortolasci; Adrienne O'Neil; Wolf Marx; Michael Berk; André F Carvalho; Michael Maes; Basant K Puri
Journal:  Life Sci       Date:  2020-10-06       Impact factor: 6.780

9.  Hydroxychloroquine Inhibits Macrophage Activation and Attenuates Renal Fibrosis After Ischemia-Reperfusion Injury.

Authors:  Haofeng Zheng; Yannan Zhang; Jiannan He; Zhe Yang; Rui Zhang; Lei Li; Zihuan Luo; Yongrong Ye; Qiquan Sun
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

Review 10.  Treatment of Cardiovascular Disease in Rheumatoid Arthritis: A Complex Challenge with Increased Atherosclerotic Risk.

Authors:  Saba Ahmed; Benna Jacob; Steven E Carsons; Joshua De Leon; Allison B Reiss
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.